Funding
The funding of NAMI by multiple pharmaceutical companies was exposed by the investigative magazine Mother Jones in 1999, including that an Eli Lilly & Company executive was then "on loan" to NAMI working out of NAMI headquarters.
NAMI receives considerably more than half its budget from pharmaceutical companies, and because of this was accused of a conflict of interest by a prominent NAMI member, E. Fuller Torrey (in 2008), and of failing to disclose that funding when promoting the medications sold by its funders.
NAMI came under scrutiny by U.S. Senator Charles E. Grassley in April 2009. Senator Grassley's investigation of NAMI confirmed that a majority of their funding was coming from the pharmaceutical companies.
In a story written by New York Times Journalist Gardiner Harris in 2009, NAMI received over 66 percent of their funding from Pharma. Gardiner, reporting off the findings of a Senate Investigation conducted by Senator Grassley (R) of Iowa. (Harris, Gardinder. New York Times, October 21, 2009)
Read more about this topic: National Alliance On Mental Illness